The nucleic acid amplification testing market was valued at $4.6 billion in 2022 and is estimated to reach $9.1 billion by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032. Nucleic acid amplification testing, also known as NAAT, is a type of laboratory testing used for identification of viral infections. These tests are used for the detection of small amounts of DNA or RNA in the test sample and thus, are used for detection of bacteria or viruses in the blood or urine sample. The material of interest be detected in a small amount of test samples which proves to be the major advantage of nucleic acid amplification testing. The method involves amplification of DNA or RNA sequences using a polymerase chain reaction (PCR), strand displacement assay (SDA), or transcription-mediated assay (TMA).
Nucleic acid amplification testing (NAAT) identifies minute quantities of an organism in a specimen without the requirement for culture by taking small quantities of DNA or RNA and multiplying it many times. These methods are especially helpful for organisms that are scarce or difficult to cultivate or identify using conventional techniques. Nucleic acid amplification testing is used for detection of both qualitative and quantitative parameters for diagnosis of infections such as hepatitis B, hepatitis C, cytomegalovirus, human T-cell lymphotropic virus, respiratory virus infections, and sexually transmitted infections and others. As the incidences of these infections are on the rise, there is an increasing demand for the nucleic acid amplification testing which boosts market growth globally.
In addition, surge in demand for rapid diagnostic testing and increase in R&D activities to develop advance diagnostic techniques are the major factors driving the growth of the nucleic acid amplification testing market. Key players in the market invest on a large scale to develop new diagnostic tests that are highly precise and require less time as compared to traditional methods.
However, lack of skilled laboratory personnels and limited awareness among the people in low- and middle-income countries are anticipated to hamper the market growth. As people in the underdeveloped countries have limited awareness, the diseases and infections go undiagnosed, thereby acting as a restraint to market growth.
On the other hand, a rise in investment by the key players is anticipated to boost the market growth in the coming years. The key players in the market are investing on a large scale to innovate and develop new diagnostic procedures that are efficient and require less time as compared to the traditional methods. As newer tests are developed, they are expected to boost market growth during the forecast period.
The nucleic acid amplification testing market is segmented on the basis of technology, application, end user, and region. By technology, the market is segmented into polymerase chain reaction (PCR) tests, and isothermal nucleic acid amplification technology (INAAT) test. The INAAT segment is further divided into loop mediated isothermal amplification (LAMP), transcription mediated amplification (TMA), nucleic acid sequence based amplification (NASBA), helicase dependent amplification (HDA), rolling circle amplification (RCA) and others. On the basis of application, the market is categorized into infectious disease testing, oncology testing and other. On the basis of end user, the market is divided into hospitals-based laboratories, central, reference and standalone laboratories, and others.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. and New England Biolabs.
Nucleic acid amplification testing (NAAT) identifies minute quantities of an organism in a specimen without the requirement for culture by taking small quantities of DNA or RNA and multiplying it many times. These methods are especially helpful for organisms that are scarce or difficult to cultivate or identify using conventional techniques. Nucleic acid amplification testing is used for detection of both qualitative and quantitative parameters for diagnosis of infections such as hepatitis B, hepatitis C, cytomegalovirus, human T-cell lymphotropic virus, respiratory virus infections, and sexually transmitted infections and others. As the incidences of these infections are on the rise, there is an increasing demand for the nucleic acid amplification testing which boosts market growth globally.
In addition, surge in demand for rapid diagnostic testing and increase in R&D activities to develop advance diagnostic techniques are the major factors driving the growth of the nucleic acid amplification testing market. Key players in the market invest on a large scale to develop new diagnostic tests that are highly precise and require less time as compared to traditional methods.
However, lack of skilled laboratory personnels and limited awareness among the people in low- and middle-income countries are anticipated to hamper the market growth. As people in the underdeveloped countries have limited awareness, the diseases and infections go undiagnosed, thereby acting as a restraint to market growth.
On the other hand, a rise in investment by the key players is anticipated to boost the market growth in the coming years. The key players in the market are investing on a large scale to innovate and develop new diagnostic procedures that are efficient and require less time as compared to the traditional methods. As newer tests are developed, they are expected to boost market growth during the forecast period.
The nucleic acid amplification testing market is segmented on the basis of technology, application, end user, and region. By technology, the market is segmented into polymerase chain reaction (PCR) tests, and isothermal nucleic acid amplification technology (INAAT) test. The INAAT segment is further divided into loop mediated isothermal amplification (LAMP), transcription mediated amplification (TMA), nucleic acid sequence based amplification (NASBA), helicase dependent amplification (HDA), rolling circle amplification (RCA) and others. On the basis of application, the market is categorized into infectious disease testing, oncology testing and other. On the basis of end user, the market is divided into hospitals-based laboratories, central, reference and standalone laboratories, and others.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. and New England Biolabs.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid amplification testing market analysis from 2022 to 2032 to identify the prevailing nucleic acid amplification testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the nucleic acid amplification testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global nucleic acid amplification testing market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By End-user
- Hospital Based Laboratories
- Central, Reference and Standalone Laboratories
- Others
By Technology
- Polymerase Chain Reaction (PCR) Tests
- Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
- Type
- Loop mediated isothermal amplification (LAMP)
- Transcription mediated amplification (TMA)
- Nucleic acid sequence based amplification (NASBA)
- Helicase dependent amplification (HDA)
- Rolling circle amplification (RCA)
- Others
By Application
- Infectious Disease Testing
- Oncology Testing
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Grifols, S.A.
- Hologic, Inc.
- Illumina Inc.
- F. Hoffmann-La Roche Ltd.
- Eiken Chemical Co., Ltd.
- BioMerieux SA
- Abbott Laboratories
- Perkin Elmer Inc
- Siemens AG
- New England Biolabs.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TECHNOLOGY
CHAPTER 5: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION
CHAPTER 6: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USER
CHAPTER 7: NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The nucleic acid amplification testing market is likely to experience a significant growth rate of 6.6% from 2023-2032 owing to increasing market demand from diagnostics and biotech sector.Nucleic acid amplification test is a cutting-edge molecular diagnostic technique used to amplify and detect specific genetic material, such DNA or RNA, in biological samples. This technique makes it possible to precisely identify and quantify genetic sequences, making it a crucial tool in a variety of sectors including clinical diagnostics, the detection of infectious diseases, genetic research, and forensics. Nucleic acid amplification testing is a molecular diagnostic technique used for detection of various infectious diseases such as HIV, tuberculosis, and cancer, such as cervical cancer. NAAT offers several advantages over the traditional diagnostic techniques, which increases its demand in the healthcare sector.
Key factors driving the growth of the nucleic acid amplification testing market are attributed to the surge in demand for advanced diagnostic techniques, rise in incidences of infectious diseases and surge in prevalence of cancer cases. Growing incidences of infectious diseases is the major driver for market growth. Infectious diseases such as malaria and tuberculosis are growing at an alarming rate which increases the demand for early diagnosis of diseases.
For instance, there were 8,300 reported TB cases in U.S. in 2022 with up to 13 million estimated number of people living with latent TB infection. Such a huge burden of infectious diseases increases the demand for accurate and precise diagnostic technologies such as nucleic acid amplification testing. This propels the growth of the market.
The surge in prevalence of cancer cases is also a major driving factor for nucleic acid amplification testing market. Nucleic acid amplification testing (NAAT) is a versatile molecular diagnostic technique used for the detection of various types of cancer. It is primarily employed to identify specific genetic mutations, alterations, or biomarkers associated with cancer cells. This contributes to market growth.
In addition, technological advancements in the diagnostic sector are also boosting the market growth. These technological advancements simplified the diagnostic procedures, reduced the cost and timeline for disease diagnosis, and increased the overall efficacy of the procedures. In addition, AI and automation in systems used for analysis have made early diagnosis and treatment possible for chronic as well as acute diseases.
Furthermore, rising awareness about point of care (POC) testing is anticipated to boost the market growth during the forecast period. Point of care testing may be defined as the testing done near or at the site of patient care. This helps in providing rapid information and improving patient outcomes. The POC testing offers several advantages such as faster access to diagnosis, allowing patients and residents to quickly get the needed care, faster access to treatments due to faster diagnosis by nurses and physicians and reduced hospital stays.
The nucleic acid amplification testing market is segmented on the basis of technology, application, end user, and region. By technology, the market is segmented into polymerase chain reaction (PCR) tests, and isothermal nucleic acid amplification technology (INAAT) test. On the basis of application, the market is categorized into infectious disease testing, oncology testing and other. On the basis of end user, the market is divided into hospitals-based laboratories, central, reference and standalone laboratories, and others.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). The key players profiled in the study include Hologic, Inc., Grifols, S.A., BioMerieux SA, Illumina Inc., Abbott Laboratories, Perkin Elmer Inc, F. Hoffmann-La Roche Ltd., Siemens AG, Eiken Chemical Co., Ltd. and New England Biolabs. The players in the market have been actively engaged in the adoption of various strategies such as product approval and product launch to remain competitive and gain an advantage over the competitors in the market.
For instance, in May 2022, Grifols announced that it has received FDA approval for the Procleix Panther System for use with the following U.S. licensed products Procleix Ultrio Elite Assay, Procleix WNV Assay, Procleix Zika Virus Assay and the Procleix Babesia Assay.
Key Market Insights
By technology, the polymerase chain reaction PCR tests segment was the highest revenue contributor to the market and is estimated to reach $7.7 billion by 2032, with a CAGR of 6.7%.By application, the infectious disease testing segment dominated the global market and is expected to be the fastest-growing segment during the forecast period.
By end user, the central, reference and standalone laboratories segment dominated the market in 2022 whereas the hospital-based laboratories segment is anticipated to be the fastest growing segment during the forecast period.
Based on region, North America garnered the largest revenue share in 2022 whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Grifols, S.A.
- Hologic, Inc.
- Illumina Inc.
- F. Hoffmann-La Roche Ltd.
- Eiken Chemical Co., Ltd.
- BioMerieux SA
- Abbott Laboratories
- Perkin Elmer Inc
- Siemens AG
- New England Biolabs.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
